Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial of Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in Patients With Previously Untreated Metastatic or Unresectable Colorectal Cancer

NCT03050814 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03050814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03050814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial of Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in Patients With Previously Untreated Metastatic or Unresectable Colorectal Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Terminated
Start date
April 5, 2017
Completion date
August 25, 2021
Enrollment
30 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal adenocarcinoma, colorectal cancer, colorectal carcinoma, colorectal neoplasms, colorectal tumors